Biomedicines (Dec 2022)

New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside… and Back

  • Alfredo Parra-Lucares,
  • Esteban Romero-Hernández,
  • Eduardo Villa,
  • Sebastián Weitz-Muñoz,
  • Geovana Vizcarra,
  • Martín Reyes,
  • Diego Vergara,
  • Sergio Bustamante,
  • Marcelo Llancaqueo,
  • Luis Toro

DOI
https://doi.org/10.3390/biomedicines11010070
Journal volume & issue
Vol. 11, no. 1
p. 70

Abstract

Read online

Heart failure with preserved ejection fraction (HFpEF) is a growing public health problem in nearly 50% of patients with heart failure. Therefore, research on new strategies for its diagnosis and management has become imperative in recent years. Few drugs have successfully improved clinical outcomes in this population. Therefore, numerous attempts are being made to find new pharmacological interventions that target the main mechanisms responsible for this disease. In recent years, pathological mechanisms such as cardiac fibrosis and inflammation, alterations in calcium handling, NO pathway disturbance, and neurohumoral or mechanic impairment have been evaluated as new pharmacological targets showing promising results in preliminary studies. This review aims to analyze the new strategies and mechanical devices, along with their initial results in pre-clinical and different phases of ongoing clinical trials for HFpEF patients. Understanding new mechanisms to generate interventions will allow us to create methods to prevent the adverse outcomes of this silent pandemic.

Keywords